<DOC>
	<DOC>NCT01460160</DOC>
	<brief_summary>The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia</brief_summary>
	<brief_title>Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Newly diagnosed Philadelphia chromosome positive Acute Lymphoblastic Leukemia (ALL) Age &gt;1 year and &lt; less than 18 years old Induction chemotherapy â‰¤ 14 days according to institutional standard of care Adequate liver, renal and cardiac function Prior treatment with a Oncogene fusion protein (BCRABL) inhibitor Extramedullary involvement of the testicles Active systemic bacterial, fungal or viral infection Down syndrome</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>